Cleveland, OH, United States
Cleveland, OH, United States

Time filter

Source Type

News Article | November 29, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Diabetic Foot Ulcers - Pipeline Review, H2 2016 addition with 51 market data tables and 15 figures, spread across 157 page is available at http://www.reportsnreports.com/reports/764559-diabetic-foot-ulcers-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis ANP Technologies Inc,CardioVascular BioTherapeutics Inc,Celgene Corp,Chrysalis BioTherapeutics Inc,CytoTools AG,EyeGene Inc,FirstString Research Inc,Genentech Inc,GlaxoSmithKline Plc,Human Stem Cells Institute,Izun Pharmaceuticals Corp,Karyopharm Therapeutics Inc,Lakewood-Amedex Inc,Lytix Biopharma AS,Mallinckrodt Plc,MediWound Ltd,NovaLead Pharma Pvt Ltd,Oneness Biotech Co Ltd,Osiris Therapeutics Inc,Pherecydes Pharma SA,Plurogen Therapeutics Inc,TechnoPhage SA,TGV-Laboratories,Theravasc Inc,Topadur Pharma AG,USV Pvt Ltd,viDA Therapeutics Inc,ViroMed Co Ltd] Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764559premium report price at US$2000 for a single user PDF license).


Allen J.D.,Duke University | Giordano T.,Theravasc | Kevil C.G.,Health science Center Shreveport
Nitric Oxide - Biology and Chemistry | Year: 2012

Peripheral artery disease (PAD) represents a burgeoning form of cardiovascular disease associated with significant clinical morbidity and increased 5 year cardiovascular disease mortality. It is characterized by impaired blood flow to the lower extremities, claudication pain and severe exercise intolerance. Pathophysiological factors contributing to PAD include atherosclerosis, endothelial cell dysfunction, and defective nitric oxide metabolite physiology and biochemistry that collectively lead to intermittent or chronic tissue ischemia. Recent work from our laboratories is revealing that nitrite/nitrate anion and nitric oxide metabolism plays an important role in modulating functional and pathophysiological responses during this disease. In this review, we discuss experimental and clinical findings demonstrating that nitrite anion acts to ameliorate numerous pathophysiological events associated with PAD and chronic tissue ischemia. We also highlight future directions for this promising line of therapy. © 2012 Elsevier Inc. All rights reserved.


Patent
Theravasc | Date: 2015-09-08

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO_(2)^()). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.


Patent
Theravasc | Date: 2012-04-13

The present invention relates to compositions of nitrite and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition of inorganic nitrite, or a pharmaceutically acceptable salt thereof, for supplementation in subjects with diabetes, peripheral artery diseases or in patients with risk factors associated with cardiovascular diseases.


Patent
Theravasc | Date: 2014-12-22

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO_(2)^()). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).


Patent
Theravasc | Date: 2010-10-14

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO_(2)^()). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.


Patent
Theravasc | Date: 2010-05-26

Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment.


Patent
Theravasc | Date: 2015-02-19

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO_(2)^()). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.


Patent
Theravasc | Date: 2013-02-20

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO_(2)^()). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).


Loading Theravasc collaborators
Loading Theravasc collaborators